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EDITORIAL COMMENT
In-Stent Restenosis:
Should an Old Device
Treat a New Problem?*
Joseph P. Carrozza, Jr., MD, FACC
Boston, Massachusetts
Thirty-five years after Charles Dotter first proposed the
concept of an endovascular prosthesis, stenting has now
emerged as the dominant technology for percutaneous
coronary revascularization (1). In many laboratories, more
than half of all patients undergoing catheter-based inter-
vention receive at least one stent, and in some the use of
stents approaches 80%. Although originally approved as
treatment for abrupt vessel closure after conventional bal-
loon angioplasty, in 1994 the landmark Stent Restenosis
Study (STRESS) and Benestent trials demonstrated for the
first time that an adjunctive therapy (i.e., elective stenting)
could significantly improve acute outcome and reduce re-
stenosis compared with balloon angioplasty alone (2,3).
Tempering this initial enthusiasm for stenting was the
need for Draconian pharmacotherapy to prevent stent
thrombosis. Colombo et al. (4) and other European inves-
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tigators elegantly showed that the routine use of high-
pressure postdilation and the substitution of the ADP-
receptor antagonist, ticlopidine, for warfarin resulted in a
reduction in the incidence of stent thrombosis, hemorrhagic
complications and length of hospitalization. Concomitantly,
the availability of new second and third generation sheath-
less stents in a variety of lengths and sizes greatly facilitated
application of stenting to lesions subsets previously deemed
“unstentable.” Given the excellent results achieved predict-
ably with stenting and the suboptimal outcome with balloon
angioplasty alone in many problematic lesions subsets, the
use of stents in these “non-STRESS/Benestent” subsets is
now routine practice. This exponential growth in the use of
coronary stents has not been without its critics, as some
charged that this trend was not driven by data, but by
preoccupation with luminal appearance rather than clinical
outcome (5). However, in the past five years a plethora of
randomized trials and prospective registries have docu-
mented the benefits of stenting for a broad range of lesions,
including saphenous vein graft lesions, prior restenosis,
chronic total occlusions and acute myocardial infarction.
Thus, the availability of better stents, abundance of evidence
supporting their benefit and the freedom from prolonged
anticoagulation has fanned the embers of “stentmania.”
While the early trials demonstrated that stenting was
associated with significantly lower rates of angiographic and
clinical restenosis, it was evident that stenting did not “cure”
restenosis. As first proposed by Kuntz et al. (6), and
subsequently verified in randomized trials, the salutory
effects of stents are due entirely to their ability to provide
predictably larger lumens, rather than an independent de-
vice effect. In fact, stenting is associated with greater late
lumen loss (the difference between posttreatment and
follow-up lumen diameter) than balloon angioplasty or
directional atherectomy. Late lumen loss after stenting is
due almost entirely to smooth muscle cell proliferation rather
than vascular remodeling, which is a significant contributor to
restenosis after balloon angioplasty or atherectomy (7). This
proliferative response is ubiquitous after arterial injury and
serves a beneficial effect by rendering the stent nonthrombo-
genic. However, since this response follows a near Gaussian
distribution, some patients develop proliferation of sufficient
magnitude to cause flow-limiting restenosis within the first
year after stent implantation. Furthermore, with improvements
in stent technology, interventional cardiologists are now “push-
ing the envelope” by stenting longer lesions, smaller vessels and
bifurcation stenoses, all of which are associated with signifi-
cantly higher rates of angiographic and clinical restenosis than
the focal, de novo lesions in large vessels treated in the
STRESS and Benestent trials. For example, stenting long
lesions in small vessels in diabetic patients may be associated
with recurrence rates that exceed 50%.
Based on conservative assumptions, it is estimated that
approximately 25,000 to 50,000 patients a year in the U.S.
will require treatment for in-stent restenosis. Thus, the
management of this problem is highly relevant to contem-
porary practice. It is important to remember that patients
with in-stent restenosis who are asymptomatic, without
provocable ischemia have excellent long-term prognosis and
may be managed medically (8). However, when in-stent
restenosis results in myocardial ischemia, luminal reenlarge-
ment can be achieved in almost all patients by a variety of
catheter-based techniques. The initial experience for treat-
ment of in-stent restenosis involved balloon dilation within
the stent. In the first large series of percutaneous treatment
of in-stent restenosis, Baim et al. (9) demonstrated that
balloon dilation was associated with acute success in all
patients, without need for additional anticoagulation. The
excellent acute angiographic appearance achieved usually
with only one balloon inflation suggested that in-stent
restenosis could be effectively treated in a cost-effective and
straightforward manner using a “low-tech” solution, balloon
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angioplasty. However, the optimism generated by this
approach was dampened by a relatively high rate of recur-
rent restenosis (;50%) in this series (limited by angio-
graphic follow-up of only 50%).
In the this issue of the Journal, Bossi et al. (10) report a
target vessel revascularization rate of only 21.4% after
balloon dilation of in-stent restenosis in 234 patients. This
encouraging outcome is in accord with earlier, smaller series
reporting clinical recurrence rates of 11% to 35% (11–13).
Since repeat dilation is the least technically demanding and
cheapest way to treat in-stent restenosis, it is tempting to
view these studies as justification for balloon-based strate-
gies. However, seminal observations by Kimura et al. (14)
relating morphology of in-stent restenosis to subsequent
risk of recurrent restenosis after balloon angioplasty have
enlightened us to the fact that not all in-stent restenosis
responds favorably to repeat dilation. Their report of an
angiographic restenosis rate of 75% for stents with a diffuse
pattern of restenosis (compared with only 8% for focal
in-stent restenosis) was sobering. These findings are cor-
roborated by contemporary series by Eltchaninoff et al. (13)
and Bauters et al. (11), both of whom reported significantly
higher rates of angiographic restenosis for balloon dilation
of diffuse, compared with focal, in-stent restenosis. More
importantly, patients with diffuse in-stent morphology are
significantly more likely to require repeat revascularization
procedures after balloon angioplasty. Target vessel revascu-
larization rates of 25% to 63% have been reported after
balloon dilation of diffuse in-stent restenosis (11–13,15). In
this study, repeat revascularization was required in 26.7%
and 31.1% of patients with diffuse ($10 mm) and prolifer-
ative ($10 mm and extending beyond the stent margins)
patterns of in-stent restenosis, respectively. In contrast,
repeat revascularization was required in only 12.5% of
patients with focal in-stent restenosis. Furthermore, pa-
tients with diffuse in-stent restenosis treated by atherectomy
were excluded from their analysis. If atherectomy were
chosen based on operator perception that those lesions
would respond poorly to balloon dilation, their exclusion
may represent a selection bias toward better outcome in this
series. The study also confirmed that early (,90 days)
presentation of restenosis, nonfocal morphology and smaller
posttreatment lumen diameter are all independently associ-
ated with the need for subsequent revascularization. These
important observations should underscore the fact that
patients with early onset or diffuse in-stent restenosis represent
a high-risk subset and may require adjunctive treatment be-
yond balloon dilation. In addition, the “bigger is better”
paradigm linking acute angiographic and late clinical outcome
also applies to treatment of in-stent restenosis as well.
Why is balloon angioplasty of diffuse in-stent restenosis
plagued by such high recurrence rates? The mechanism of
luminal enlargement after balloon expansion includes a
combination of stent expansion (56% of area gain) and a
decrease in hyperplastic material resulting from both plaque
compression and extrusion through the struts (44% of area
gain) (16). Despite high-pressure dilation, the residual
stenosis is relatively high (;18%), and the cross-section area
within the stent is almost always less than that obtained
when the stent was originally deployed. Furthermore, using
intravascular ultrasound, Shiran and colleagues (17) have
elegantly demonstrated that immediate recoil of hyperplastic
material compressed and extruded through the stent struts
further erodes approximately 20% of the initial gain
achieved with balloon dilation. This early reduction in
lumen cross-sectional area is most pronounced after treat-
ment of diffuse in-stent restenosis, probably due to the
higher total plaque volume.
These observations became the impetus for investigation
of other strategies employing “debulking” techniques, in
which a portion of the plaque within the stent is removed or
ablated before balloon dilation. Several investigators have
reported repeat revascularization rates from 20% to 38%
after rotational atherectomy for diffuse in-stent restenosis
(15,18,19). In a retrospective analysis, Dauerman and col-
leagues reported a reduction in subsequent target vessel
revascularization from 46% to 28% in patients with diffuse
in-stent restenosis treated with rotational or directional
atherectomy compared with balloon angioplasty alone. In-
dependent predictors of target vessel revascularization in-
cluded diabetes mellitus, lesion length and smaller post-
treatment lumen diameter. Similar results have also been
reported after the use of directional atherectomy or excimer
laser angioplasty (16,20,21). In the randomized Rotablator
Versus Balloon for Stent Restenosis trial, 150 patients with
in-stent restenosis were randomized to treatment with
balloon angioplasty or rotational atherectomy. Patients in
the rotational atherectomy cohort had significantly greater
lumen area gain and a 53% reduction in clinical restenosis
(20% vs. 43%) (19). The benefits of rotational atherectomy
in the treatment of diffuse in-stent restenosis are best
explained by the observations that tissue removal is the
predominant mechanism of luminal enlargement, with a
smaller contribution of compression and extrusion of plaque
and additional stent expansions (18,19).
Despite these promising results observed with debulking
of in-stent restenosis, many patients with diffuse in-stent
restenoses will require additional interventions to treat this
aggressive proliferative response, which some have termed
“malignant restenosis.” Since in-stent restenosis is due
almost entirely to a proliferative process, therapies that can
inhibit smooth muscle cell division offer the best hope for
the prevention and treatment of in-stent restenosis. The
observations that ionizing radiation is effective in the treat-
ment of other benign proliferative disorders (e.g., occular
pterygium and keloid formation) provided the theoretic
basis for the investigation of brachytherapy as a treatment
for restenosis. In the Scripps trial, patients at high risk for
restenosis (the majority of whom had in-stent restenosis)
were randomized to gamma irradiation with 192I or placebo
(21). Patients in the radiation cohort had a marked reduc-
tion in angiographic restenosis (17% vs. 54%) and target
lesion revascularization (12% vs. 45%). These dramatic
benefits of gamma irradiation were confirmed in the larger
multicenter Gamma 1 trial where in-stent angiographic
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restenosis was reduced from 52% to 22% in lesions treated
with gamma irradiation (22). In the Washington Radiation
for In-Stent Restenosis Trial (WRIST), in which patients
with in-stent restenoses in either native coronary arteries or
saphenous vein grafts were randomized to intracoronary
gamma irradiation or placebo, a significant reduction in
angiographic restenosis (19% vs. 58%) and subsequent
target lesion revascularization (26% vs. 67%) was observed
in the active treatment cohort (23). The long-term outcome
of patients with in-stent restenosis treated with beta irradi-
ation is being evaluated in the randomized Stents and
Radiation Therapy trial in which patients are randomized to
beta irradiation with a 90Strontium/Yttrium source (Beta-
Cath System, Novoste Corp, Norcross, Georgia) or placebo.
While the preliminary findings from this study suggest that
intravascular radiation therapy reduces angiographic reste-
nosis by 47% and target vessel revascularization by 34% (24).
Issues such as dosimetry, radiation source, importance of
source “centering,” “geographic mismatch” and long-term
safety must be thoroughly addressed before widespread
adoption of this promising therapy can be recommended.
While there are many unresolved issues regarding the
treatment of in-stent restenosis, several principles have
emerged over the past few years. First, interventional
cardiologists should heed the old adage that “an ounce of
prevention is worth a pound of cure” and strive to optimize
stent expansion at the time of deployment, rather than
looking for the fastest and cheapest way to complete the
case. This may involve debulking calcified or bulky plaques
before stent placement, post-dilating the stent with larger
balloons or use of on-line quantitative angiography, intra-
vascular ultrasound or physiologic assessment to confirm
optimal stenting. Second, the “oculo-stenotic reflex” of
repeat intervention is best avoided when patients with
in-stent restenosis are asymptomatic and lack provocable
ischemia, since it carries a favorable prognosis and may regress
over time. As illustrated in this study, ischemia due to focal
in-stent restenosis can be safely and reliably treated with
balloon dilation with low likelihood of clinical recurrence. At
the present time, for the more problematic subset of patients
with diffuse in-stent restenosis, debulking before redilation allows
the operator to obtain better acute results, which offers the best
chance of long-term patency. In the future, adjunctive brachy-
therapy may reduce the exuberant cellular proliferation that still
plagues this breakthrough technology.
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